The Pharmacy Times® Pneumococcal Resource Center is a comprehensive resource for clinical news and expert insights for any infection caused by the bacteria Streptococcus pneumoniae, or pneumococcus.
April 15th 2025
Patients who received a pneumococcal conjugate vaccine 13 vaccination had slightly lower incidence of severe COVID-19 outcomes, but the directions of these associations were mixed.
Pneumococcal Disease Prevention for Older Adults and the Pharmacist’s Role in an Evolving Vaccine Landscape
1.0 Credit / Immunization, Infectious Diseases
View More
Navigating the HIV Treatment Frontier: Equipping Managed Care Professionals With Strategies for Innovation, Ac...
1.5 Credits / HIV/AIDS, Infectious Diseases
View More
The Impact of Pharmacists and Pharmacy Technicians in Recognizing and Responding to Human Trafficking (Pharmac...
2.0 Credits / Human Trafficking, Law
View More
Ensuring Pharmacy Technicians’ Proficiency in Risk Evaluation and Mitigation Strategies
1.0 Credit / Law, Pain Management, Opioids
View More
The Role of the Pharmacist in Influenza Prevention for At-Risk Adults: Strategies to Enhance Immunization
1.5 Credits / Infectious Diseases
View More
The Essential Role of Pharmacists in Improving Influenza Vaccination Coverage: Strategies to Increase Vaccine ...
1.0 Credit / Immunization, Infectious Diseases
View More
The Role of Pharmacists in Pneumococcal Prevention: Strategies to Improve Vaccine Uptake
1.0 Credit / Immunization, Infectious Diseases, Pulmonology
View More
Insights in Influenza Immunization: The Long-Term Care Pharmacist’s Role in Improving Health Outcomes in At-Ri...
1.0 Credit / Immunization, Infectious Diseases
View More
Exploring HIV Long-Acting Injectable Uptake: How Pharmacists Can Encourage Long-Acting Injectables to Stem the...
1.5 Credits / HIV/AIDS, Infectious Disease
View More
Beyond the Spots: Management of Measles
1.0 Credit / Infectious Disease, Immunization
View More
FDA Approves Expanded Indication for Vaxneuvance Pneumococcal Vaccine
June 22nd 2022Vaxneuvance is now indicated for the prevention of invasive disease caused by Streptococcus pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, 22F, 23F and 33F in individuals 6 weeks of age and older.
Read More